NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.

Don't have an account? Subscribe

Ibrutinib added to standard-of-care therapy improves PFS by 50% for older patients with mantle cell lymphoma

By Priscilla Lynch - 05th Jul 2022


Ibrutinib combined with bendamustine-rituximab improved PFS by 50 per cent for older patients with newly-diagnosed mantle cell lymphoma compared to patients who received a placebo plus bendamustine-rituximab, according to new research reported at the 2022 ASCO Annual Meeting. 

The double-blind phase 3 SHINE trial randomly assigned 523 patients age 65 or older (median age 71 years) with mantle cell lymphoma, at 203 international study locations, to either ibrutinib plus bendamustine-rituximab (261 patients) or placebo plus bendamustine-rituximab (262 patients). Both study groups had similar baseline characteristics, with a median follow-up time of seven years. 

Median PFS was 80.6 months with ibrutinib in combination with bendamustine-rituximab and rituximab maintenance; a 50 per cent improvement over the group that received a placebo with bendamustine-rituximab and rituximab maintenance, which saw a median PFS of 52.9 months. The complete response rate was 65.5 per cent in the ibrutinib group and 57.6 per cent in the placebo group. There was no difference in OS between treatment groups at the time of the latest assessment of outcomes. 

The safety profile of the combined treatment was consistent with the known profiles of ibrutinib and bendamustine-rituximab. Quality-of-life was also similar in both groups. 

“The SHINE study is the first international phase 3 trial to show a positive impact of ibrutinib combined with standard-of-care treatment in this disease. The progression-free survival is substantially longer than the common treatment options used today, which is an important clinical advancement,” said lead author Prof Michael Wang, Professor at the University of Texas MD Anderson Cancer Center, Houston, US. 

“Older people are generally underrepresented in clinical trials. Some lymphoma treatments, including intensive chemotherapy, targeted agents, or transplantation may have excessive toxicities in older patients, making them unsuitable choices for treatment. Patients with mantle cell lymphoma are often older and their inclusion in clinical trials can provide us with a better understanding of the balance between benefit and toxicity of treatments in their age group. Results from this trial bring new hope to newly diagnosed, older patients with this rare cancer who have had too few treatment options,” said ASCO Chief Medical Officer and Executive Vice President Prof Julie R Gralow.

Leave a Reply

Latest Issue
The Medical Independent 21st November 2023

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read